New publication: Validating a bespoke 96-well plate for high-throughput drug susceptibility testing of M. tuberculosis Philip Fowler, 28th August 201829th September 2018 This paper, published in Antimicrobial Agents and Chemotherapy, determines the reproducibility and accuracy of minimum inhibitory concentrations for a panel of 14 different anti-TB compounds using a specifically designed 96-well plate (called UKMYC5) manufactured by Thermo Fisher. Since the UKMYC5 plate is being used by the CRyPTIC consortium to measure the drug susceptibility profiles of >30,000 clinical TB samples collected worldwide between now and 2020, this manuscript lays the foundations for this large and ambitious tuberculosis research project. It is free to read and download, and the paper briefly mentions my AMyGDA software which we will be using as an independent measuring technique to quality control the measurements made by the laboratory scientists. You can download and AMyGDA software from here. A manuscript is currently under review – you can read a preprint here. The bacterial growth on the UKMYC5 plates are also being classified by a Citizen Science project I have setup, BashTheBug. Share this:TwitterBlueskyEmailLinkedInMastodon Related antimicrobial resistance clinical microbiology publication tuberculosis
publication New Publication: Membrane Compartmentalization Reduces the Mobility of Lipids. 23rd September 201629th September 2018 Lipids are not free to diffuse around the cell membrane. Rather they are constrained not… Share this:TwitterBlueskyEmailLinkedInMastodon Read More
antimicrobial resistance New Publication: Structure of MmpL3 21st July 202121st July 2021 Oliver Adams successfully elucidated the structure of the M. tuberculosis MmpL3 membrane transporter using cryo-EM… Share this:TwitterBlueskyEmailLinkedInMastodon Read More
antimicrobial resistance New preprint: predicting rifampicin resistance 16th August 202416th August 2024 In this preprint we train a series of machine learning models on protein mutations found… Share this:TwitterBlueskyEmailLinkedInMastodon Read More